Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) with ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)
Arsenic Trioxide, ATRA, Gemtuzamab Ozogamicin
If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if the combination of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) can help to control acute promyelocytic leukemia (APL). The safety of this drug combination will also be studied.
Disease Group: Leukemia
Treatment Agent: Arsenic Trioxide, ATRA, Gemtuzamab Ozogamicin
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Pfizer, Inc.
IRB Review and Approval Date: 10/05/2011
Recruitment Status: Open
Projected Accrual: 150
Information and next steps
For general questions about clinical trials: